Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

Advanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this study, we assessed the potential role of bone morphogenetic protein 8A (BMP8A) as a novel target involved in liver fibrosis progression. Histological assessment...

Full description

Saved in:
Bibliographic Details
Published inBiomarker research Vol. 11; no. 1; p. 46
Main Authors Marañón, Patricia, Isaza, Stephania C, Fernández-García, Carlos Ernesto, Rey, Esther, Gallego-Durán, Rocío, Montero-Vallejo, Rocío, de Cía, Javier Rodríguez, Ampuero, Javier, Valverde, Ángela M, Romero-Gómez, Manuel, García-Monzón, Carmelo, González-Rodríguez, Águeda
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 27.04.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Advanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this study, we assessed the potential role of bone morphogenetic protein 8A (BMP8A) as a novel target involved in liver fibrosis progression. Histological assessment and BMP8A expression were determined in different murine models of hepatic fibrosis. Furthermore, serum BMP8A was measured in mice with bile duct ligation (BDL), in 36 subjects with histologically normal liver (NL) and in 85 patients with biopsy-proven non-alcoholic steatohepatitis (NASH): 52 with non- or mild fibrosis (F0-F2) and 33 with advanced fibrosis (F3-F4). BMP8A expression and secretion was also determined in cultured human hepatocyte-derived (Huh7) and human hepatic stellate (LX2) cells stimulated with transforming growth factor ꞵ (TGFꞵ). Bmp8a mRNA levels were significantly upregulated in livers from fibrotic mice compared to control animals. Notably, serum BMP8A levels were also elevated in BDL mice. In addition, in vitro experiments showed increased expression and secretion to the culture supernatant of BMP8A in both Huh7 and LX2 cells treated with TGFꞵ. Noteworthy, we found that serum BMP8A levels were significantly higher in NASH patients with advanced fibrosis than in those with non- or mild fibrosis. In fact, the AUROC of circulating BMP8A concentrations to identify patients with advanced fibrosis (F3-F4) was 0.74 (p˂0.0001). Moreover, we developed an algorithm based on serum BMP8A levels that showed an AUROC of 0.818 (p˂0.0001) to predict advanced fibrosis in NASH patients. This study provides experimental and clinical evidence indicating that BMP8A is a novel molecular target linked to liver fibrosis and introduces an efficient algorithm based on serum BMP8A levels to screen patients at risk for advanced hepatic fibrosis.
AbstractList BACKGROUND & AIMSAdvanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this study, we assessed the potential role of bone morphogenetic protein 8A (BMP8A) as a novel target involved in liver fibrosis progression.METHODSHistological assessment and BMP8A expression were determined in different murine models of hepatic fibrosis. Furthermore, serum BMP8A was measured in mice with bile duct ligation (BDL), in 36 subjects with histologically normal liver (NL) and in 85 patients with biopsy-proven non-alcoholic steatohepatitis (NASH): 52 with non- or mild fibrosis (F0-F2) and 33 with advanced fibrosis (F3-F4). BMP8A expression and secretion was also determined in cultured human hepatocyte-derived (Huh7) and human hepatic stellate (LX2) cells stimulated with transforming growth factor ꞵ (TGFꞵ).RESULTSBmp8a mRNA levels were significantly upregulated in livers from fibrotic mice compared to control animals. Notably, serum BMP8A levels were also elevated in BDL mice. In addition, in vitro experiments showed increased expression and secretion to the culture supernatant of BMP8A in both Huh7 and LX2 cells treated with TGFꞵ. Noteworthy, we found that serum BMP8A levels were significantly higher in NASH patients with advanced fibrosis than in those with non- or mild fibrosis. In fact, the AUROC of circulating BMP8A concentrations to identify patients with advanced fibrosis (F3-F4) was 0.74 (p˂0.0001). Moreover, we developed an algorithm based on serum BMP8A levels that showed an AUROC of 0.818 (p˂0.0001) to predict advanced fibrosis in NASH patients.CONCLUSIONThis study provides experimental and clinical evidence indicating that BMP8A is a novel molecular target linked to liver fibrosis and introduces an efficient algorithm based on serum BMP8A levels to screen patients at risk for advanced hepatic fibrosis.
Background & Aims Advanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this study, we assessed the potential role of bone morphogenetic protein 8A (BMP8A) as a novel target involved in liver fibrosis progression. Methods Histological assessment and BMP8A expression were determined in different murine models of hepatic fibrosis. Furthermore, serum BMP8A was measured in mice with bile duct ligation (BDL), in 36 subjects with histologically normal liver (NL) and in 85 patients with biopsy-proven non-alcoholic steatohepatitis (NASH): 52 with non- or mild fibrosis (F0-F2) and 33 with advanced fibrosis (F3-F4). BMP8A expression and secretion was also determined in cultured human hepatocyte-derived (Huh7) and human hepatic stellate (LX2) cells stimulated with transforming growth factor êµ (TGFêµ). Results Bmp8a mRNA levels were significantly upregulated in livers from fibrotic mice compared to control animals. Notably, serum BMP8A levels were also elevated in BDL mice. In addition, in vitro experiments showed increased expression and secretion to the culture supernatant of BMP8A in both Huh7 and LX2 cells treated with TGFêµ. Noteworthy, we found that serum BMP8A levels were significantly higher in NASH patients with advanced fibrosis than in those with non- or mild fibrosis. In fact, the AUROC of circulating BMP8A concentrations to identify patients with advanced fibrosis (F3-F4) was 0.74 (pË0.0001). Moreover, we developed an algorithm based on serum BMP8A levels that showed an AUROC of 0.818 (pË0.0001) to predict advanced fibrosis in NASH patients. Conclusion This study provides experimental and clinical evidence indicating that BMP8A is a novel molecular target linked to liver fibrosis and introduces an efficient algorithm based on serum BMP8A levels to screen patients at risk for advanced hepatic fibrosis. Keywords: Liver fibrosis, Bone morphogenetic proteins, BMP8A, Non-invasive diagnosis, Hepatic stellate cells
Advanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this study, we assessed the potential role of bone morphogenetic protein 8A (BMP8A) as a novel target involved in liver fibrosis progression. Histological assessment and BMP8A expression were determined in different murine models of hepatic fibrosis. Furthermore, serum BMP8A was measured in mice with bile duct ligation (BDL), in 36 subjects with histologically normal liver (NL) and in 85 patients with biopsy-proven non-alcoholic steatohepatitis (NASH): 52 with non- or mild fibrosis (F0-F2) and 33 with advanced fibrosis (F3-F4). BMP8A expression and secretion was also determined in cultured human hepatocyte-derived (Huh7) and human hepatic stellate (LX2) cells stimulated with transforming growth factor êµ (TGFêµ). Bmp8a mRNA levels were significantly upregulated in livers from fibrotic mice compared to control animals. Notably, serum BMP8A levels were also elevated in BDL mice. In addition, in vitro experiments showed increased expression and secretion to the culture supernatant of BMP8A in both Huh7 and LX2 cells treated with TGFêµ. Noteworthy, we found that serum BMP8A levels were significantly higher in NASH patients with advanced fibrosis than in those with non- or mild fibrosis. In fact, the AUROC of circulating BMP8A concentrations to identify patients with advanced fibrosis (F3-F4) was 0.74 (pË0.0001). Moreover, we developed an algorithm based on serum BMP8A levels that showed an AUROC of 0.818 (pË0.0001) to predict advanced fibrosis in NASH patients. This study provides experimental and clinical evidence indicating that BMP8A is a novel molecular target linked to liver fibrosis and introduces an efficient algorithm based on serum BMP8A levels to screen patients at risk for advanced hepatic fibrosis.
Abstract Background & Aims Advanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this study, we assessed the potential role of bone morphogenetic protein 8A (BMP8A) as a novel target involved in liver fibrosis progression. Methods Histological assessment and BMP8A expression were determined in different murine models of hepatic fibrosis. Furthermore, serum BMP8A was measured in mice with bile duct ligation (BDL), in 36 subjects with histologically normal liver (NL) and in 85 patients with biopsy-proven non-alcoholic steatohepatitis (NASH): 52 with non- or mild fibrosis (F0-F2) and 33 with advanced fibrosis (F3-F4). BMP8A expression and secretion was also determined in cultured human hepatocyte-derived (Huh7) and human hepatic stellate (LX2) cells stimulated with transforming growth factor ꞵ (TGFꞵ). Results Bmp8a mRNA levels were significantly upregulated in livers from fibrotic mice compared to control animals. Notably, serum BMP8A levels were also elevated in BDL mice. In addition, in vitro experiments showed increased expression and secretion to the culture supernatant of BMP8A in both Huh7 and LX2 cells treated with TGFꞵ. Noteworthy, we found that serum BMP8A levels were significantly higher in NASH patients with advanced fibrosis than in those with non- or mild fibrosis. In fact, the AUROC of circulating BMP8A concentrations to identify patients with advanced fibrosis (F3-F4) was 0.74 (p˂0.0001). Moreover, we developed an algorithm based on serum BMP8A levels that showed an AUROC of 0.818 (p˂0.0001) to predict advanced fibrosis in NASH patients. Conclusion This study provides experimental and clinical evidence indicating that BMP8A is a novel molecular target linked to liver fibrosis and introduces an efficient algorithm based on serum BMP8A levels to screen patients at risk for advanced hepatic fibrosis.
Advanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this study, we assessed the potential role of bone morphogenetic protein 8A (BMP8A) as a novel target involved in liver fibrosis progression. Histological assessment and BMP8A expression were determined in different murine models of hepatic fibrosis. Furthermore, serum BMP8A was measured in mice with bile duct ligation (BDL), in 36 subjects with histologically normal liver (NL) and in 85 patients with biopsy-proven non-alcoholic steatohepatitis (NASH): 52 with non- or mild fibrosis (F0-F2) and 33 with advanced fibrosis (F3-F4). BMP8A expression and secretion was also determined in cultured human hepatocyte-derived (Huh7) and human hepatic stellate (LX2) cells stimulated with transforming growth factor ꞵ (TGFꞵ). Bmp8a mRNA levels were significantly upregulated in livers from fibrotic mice compared to control animals. Notably, serum BMP8A levels were also elevated in BDL mice. In addition, in vitro experiments showed increased expression and secretion to the culture supernatant of BMP8A in both Huh7 and LX2 cells treated with TGFꞵ. Noteworthy, we found that serum BMP8A levels were significantly higher in NASH patients with advanced fibrosis than in those with non- or mild fibrosis. In fact, the AUROC of circulating BMP8A concentrations to identify patients with advanced fibrosis (F3-F4) was 0.74 (p˂0.0001). Moreover, we developed an algorithm based on serum BMP8A levels that showed an AUROC of 0.818 (p˂0.0001) to predict advanced fibrosis in NASH patients. This study provides experimental and clinical evidence indicating that BMP8A is a novel molecular target linked to liver fibrosis and introduces an efficient algorithm based on serum BMP8A levels to screen patients at risk for advanced hepatic fibrosis.
ArticleNumber 46
Audience Academic
Author Montero-Vallejo, Rocío
Valverde, Ángela M
Gallego-Durán, Rocío
González-Rodríguez, Águeda
Romero-Gómez, Manuel
Marañón, Patricia
de Cía, Javier Rodríguez
García-Monzón, Carmelo
Isaza, Stephania C
Rey, Esther
Fernández-García, Carlos Ernesto
Ampuero, Javier
Author_xml – sequence: 1
  givenname: Patricia
  surname: Marañón
  fullname: Marañón, Patricia
  organization: Metabolic Syndrome and Vascular Risk Laboratory, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain
– sequence: 2
  givenname: Stephania C
  surname: Isaza
  fullname: Isaza, Stephania C
  organization: Metabolic Syndrome and Vascular Risk Laboratory, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain
– sequence: 3
  givenname: Carlos Ernesto
  surname: Fernández-García
  fullname: Fernández-García, Carlos Ernesto
  organization: Metabolic Syndrome and Vascular Risk Laboratory, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain
– sequence: 4
  givenname: Esther
  surname: Rey
  fullname: Rey, Esther
  organization: Metabolic Syndrome and Vascular Risk Laboratory, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain
– sequence: 5
  givenname: Rocío
  surname: Gallego-Durán
  fullname: Gallego-Durán, Rocío
  organization: Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
– sequence: 6
  givenname: Rocío
  surname: Montero-Vallejo
  fullname: Montero-Vallejo, Rocío
  organization: Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
– sequence: 7
  givenname: Javier Rodríguez
  surname: de Cía
  fullname: de Cía, Javier Rodríguez
  organization: Metabolic Syndrome and Vascular Risk Laboratory, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain
– sequence: 8
  givenname: Javier
  surname: Ampuero
  fullname: Ampuero, Javier
  organization: Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
– sequence: 9
  givenname: Ángela M
  surname: Valverde
  fullname: Valverde, Ángela M
  organization: Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Investigaciones Biomédicas Alberto Sols (Centro Mixto CSIC-UAM), Madrid, Spain
– sequence: 10
  givenname: Manuel
  surname: Romero-Gómez
  fullname: Romero-Gómez, Manuel
  organization: Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
– sequence: 11
  givenname: Carmelo
  surname: García-Monzón
  fullname: García-Monzón, Carmelo
  organization: Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
– sequence: 12
  givenname: Águeda
  orcidid: 0000-0003-2851-2318
  surname: González-Rodríguez
  fullname: González-Rodríguez, Águeda
  email: aguedagr.phd@gmail.com, aguedagr.phd@gmail.com
  organization: Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Investigaciones Biomédicas Alberto Sols (Centro Mixto CSIC-UAM), Madrid, Spain. aguedagr.phd@gmail.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37106416$$D View this record in MEDLINE/PubMed
BookMark eNptkk1v1DAQhiNUREvpH-CAInGBQ4q_45zQatXCSpWQoHfLscepl6y92MkK_j3ebildhH2w5XnmtWf8vqxOQgxQVa8xusRYig-ZISpYgwhtEGKya8iz6owgjpq2bfHJk_1pdZHzGpUhJcO4e1Gd0hYjwbA4q_TSJzOPevJhqPtyRb2JaXsXBwgweVNvU5zAh1ouap9rXYe4g7Hufdzo9B1SPcWCgPVmqrXd6WDA1qPflYjzfYrZ51fVc6fHDBcP63l1e311u_zc3Hz5tFoubhrDWTc1VIDWFizrRe9sb5lxkhjb4a4lwmBDgXPDtBWIM4Mdlq1oba8pJ9QJKuh5tTrI2qjXapt8eeAvFbVX9wcxDUqnUtEISvbWYc40Y65oMal1p23fQlf6SgTQovXxoLWd-w1YA2FKejwSPY4Ef6eGuFMYYUY42iu8e1BI8ccMeVIbnw2Mow4Q56yIRG2HMZe8oG__QddxTqG0qlCYC0I6Tv9Sgy4V-OBiudjsRdWiZS3FXSELdfkfqkwLG2_K7zpfzo8S3h8lFGaCn9Og55zV6tvXY5YcWFP-NSdwjw3BSO09qQ6eVMWT6t6Tap_05mkrH1P-OJD-BiWK3QU
Cites_doi 10.1038/s42255-020-0214-9
10.1002/cld.1061
10.3855/jidc.4033
10.3748/wjg.v25.i30.4222
10.1111/liv.13879
10.2174/1871530319666191018170022
10.2147/IJGM.S385513
10.1126/scisignal.aal1910
10.1136/gutjnl-2014-306968
10.1055/s-0029-1216378
10.1002/hep.20701
10.1146/annurev-pathol-012615-044224
10.1016/j.metabol.2015.12.012
10.1016/j.mce.2014.11.002
10.1002/hep.27368
10.3390/cells8050457
10.1016/j.mam.2018.09.002
10.1186/1471-230X-11-91
10.1136/postgradmedj-2018-136316
10.1002/hep.24105
10.1016/j.jhep.2018.09.014
10.1007/s10620-007-9758-8
10.1242/dmm.038810
10.3390/cells9040875
10.1111/j.1572-0241.1999.01377.x
10.1055/s-2001-17550
10.1016/j.ebiom.2020.102794
10.1002/cphy.c120035
10.1136/gut.2010.216077
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID NPM
AAYXX
CITATION
ISR
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s40364-023-00489-2
DatabaseName PubMed
CrossRef
Gale In Context: Science
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Biological Science Collection
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest One Academic
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database




PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2050-7771
EndPage 46
ExternalDocumentID oai_doaj_org_article_8bdf154a44f54c48aa9adb7e918626e3
A747319562
10_1186_s40364_023_00489_2
37106416
Genre Journal Article
GeographicLocations Taiwan
Spain
United States--US
GeographicLocations_xml – name: Taiwan
– name: Spain
– name: United States--US
GrantInformation_xml – fundername: Gilead Sciences
  grantid: GLD18/00151
– fundername: Instituto de Salud Carlos III
  grantid: PI16/00853
– fundername: Instituto de Salud Carlos III
  grantid: CD20/00199
– fundername: ;
– fundername: ;
  grantid: GLD18/00151
– fundername: ;
  grantid: CD20/00199; PI16/00853
GroupedDBID -A0
0R~
53G
5VS
8FE
8FH
AAFWJ
AAJSJ
ACGFS
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AFKRA
AFPKN
AHBYD
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
ASPBG
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
C24
C6C
CCPQU
DIK
EBLON
EBS
GROUPED_DOAJ
HCIFZ
HYE
IAO
IHR
INH
INR
ISR
ITC
KQ8
LK8
M48
M7P
M~E
NPM
OK1
PGMZT
PIMPY
PROAC
RBZ
ROL
RPM
RSV
SOJ
AAYXX
CITATION
ABUWG
AZQEC
DWQXO
GNUQQ
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c549t-36eaaded4b6bfdbd4cf82cd919726c1c3e55c4ad6054c1f18767dba3523f6363
IEDL.DBID RPM
ISSN 2050-7771
IngestDate Tue Oct 22 15:15:00 EDT 2024
Tue Sep 17 21:31:15 EDT 2024
Sat Oct 05 05:22:08 EDT 2024
Thu Oct 10 17:19:53 EDT 2024
Tue Nov 19 21:04:45 EST 2024
Tue Nov 12 23:24:23 EST 2024
Sat Sep 28 21:09:34 EDT 2024
Thu Nov 21 22:44:12 EST 2024
Sat Sep 28 08:20:29 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords BMP8A
Bone morphogenetic proteins
Hepatic stellate cells
Non-invasive diagnosis
Liver fibrosis
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c549t-36eaaded4b6bfdbd4cf82cd919726c1c3e55c4ad6054c1f18767dba3523f6363
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-2851-2318
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142503/
PMID 37106416
PQID 2815622953
PQPubID 2040162
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_8bdf154a44f54c48aa9adb7e918626e3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10142503
proquest_miscellaneous_2807911585
proquest_journals_2815622953
gale_infotracmisc_A747319562
gale_infotracacademiconefile_A747319562
gale_incontextgauss_ISR_A747319562
crossref_primary_10_1186_s40364_023_00489_2
pubmed_primary_37106416
PublicationCentury 2000
PublicationDate 2023-04-27
PublicationDateYYYYMMDD 2023-04-27
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-27
  day: 27
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Biomarker research
PublicationTitleAlternate Biomark Res
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References S Arndt (489_CR27) 2015; 64
JE Puche (489_CR24) 2013; 3
F Tacke (489_CR15) 2007; 52
K Liu (489_CR20) 2020; 20
E Buzzetti (489_CR8) 2016; 65
NE Owen (489_CR17) 2020; 56
D Chung (489_CR19) 2015; 400
SK Asrani (489_CR1) 2019; 70
T Hardy (489_CR6) 2016; 11
S Cheemerla (489_CR2) 2021; 17
N Roehlen (489_CR4) 2020; 9
E Jennison (489_CR9) 2019; 95
MM Zoheiry (489_CR31) 2015; 7
N AktugDemir (489_CR14) 2014; 8
A Villar-Lorenzo (489_CR21) 2019; 12
S McPherson (489_CR11) 2010; 59
A Geerts (489_CR5) 2001; 21
ZH Lin (489_CR12) 2011; 53
FJ Wu (489_CR18) 2017; 10
J Hao (489_CR32) 2022; 15
489_CR13
A Mahli (489_CR28) 2019; 8
A Baranova (489_CR10) 2011; 11
EM Brunt (489_CR23) 1999; 94
L Zhang (489_CR25) 2012; 18
M Vacca (489_CR29) 2020; 2
M Ekstedt (489_CR7) 2015; 61
A Addante (489_CR30) 2018; 38
M Parola (489_CR3) 2019; 65
M Chayanupatkul (489_CR16) 2009; 19
GL Zou (489_CR26) 2019; 25
DE Kleiner (489_CR22) 2005; 41
References_xml – volume: 2
  start-page: 514
  issue: 6
  year: 2020
  ident: 489_CR29
  publication-title: Nat Metab
  doi: 10.1038/s42255-020-0214-9
  contributor:
    fullname: M Vacca
– volume: 17
  start-page: 365
  issue: 5
  year: 2021
  ident: 489_CR2
  publication-title: Clin Liver Dis (Hoboken)
  doi: 10.1002/cld.1061
  contributor:
    fullname: S Cheemerla
– volume: 8
  start-page: 605
  issue: 5
  year: 2014
  ident: 489_CR14
  publication-title: J Infect Dev Ctries
  doi: 10.3855/jidc.4033
  contributor:
    fullname: N AktugDemir
– volume: 25
  start-page: 4222
  issue: 30
  year: 2019
  ident: 489_CR26
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v25.i30.4222
  contributor:
    fullname: GL Zou
– volume: 38
  start-page: 1664
  issue: 9
  year: 2018
  ident: 489_CR30
  publication-title: Liver Int
  doi: 10.1111/liv.13879
  contributor:
    fullname: A Addante
– volume: 20
  start-page: 591
  issue: 4
  year: 2020
  ident: 489_CR20
  publication-title: Endocr Metab Immune Disord Drug Targets
  doi: 10.2174/1871530319666191018170022
  contributor:
    fullname: K Liu
– volume: 15
  start-page: 8539
  year: 2022
  ident: 489_CR32
  publication-title: Int J Gen Med
  doi: 10.2147/IJGM.S385513
  contributor:
    fullname: J Hao
– volume: 10
  start-page: eaal1910
  issue: 477
  year: 2017
  ident: 489_CR18
  publication-title: Sci Signal
  doi: 10.1126/scisignal.aal1910
  contributor:
    fullname: FJ Wu
– volume: 64
  start-page: 973
  issue: 6
  year: 2015
  ident: 489_CR27
  publication-title: Gut
  doi: 10.1136/gutjnl-2014-306968
  contributor:
    fullname: S Arndt
– volume: 19
  start-page: 246
  issue: 4
  year: 2009
  ident: 489_CR16
  publication-title: Eur J Pediatr Surg
  doi: 10.1055/s-0029-1216378
  contributor:
    fullname: M Chayanupatkul
– volume: 41
  start-page: 1313
  issue: 6
  year: 2005
  ident: 489_CR22
  publication-title: Hepatology
  doi: 10.1002/hep.20701
  contributor:
    fullname: DE Kleiner
– volume: 11
  start-page: 451
  year: 2016
  ident: 489_CR6
  publication-title: Annu Rev Pathol
  doi: 10.1146/annurev-pathol-012615-044224
  contributor:
    fullname: T Hardy
– volume: 65
  start-page: 1038
  issue: 8
  year: 2016
  ident: 489_CR8
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2015.12.012
  contributor:
    fullname: E Buzzetti
– volume: 400
  start-page: 48
  year: 2015
  ident: 489_CR19
  publication-title: Mol Cell Endocrinol
  doi: 10.1016/j.mce.2014.11.002
  contributor:
    fullname: D Chung
– volume: 61
  start-page: 1547
  issue: 5
  year: 2015
  ident: 489_CR7
  publication-title: Hepatology
  doi: 10.1002/hep.27368
  contributor:
    fullname: M Ekstedt
– volume: 7
  start-page: 1626
  issue: 8
  year: 2015
  ident: 489_CR31
  publication-title: Cirr Hepatocellular Carc Elec Physician
  contributor:
    fullname: MM Zoheiry
– volume: 8
  start-page: 457
  issue: 5
  year: 2019
  ident: 489_CR28
  publication-title: Cells
  doi: 10.3390/cells8050457
  contributor:
    fullname: A Mahli
– volume: 65
  start-page: 37
  year: 2019
  ident: 489_CR3
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2018.09.002
  contributor:
    fullname: M Parola
– volume: 11
  start-page: 91
  year: 2011
  ident: 489_CR10
  publication-title: BMC Gastroenterol
  doi: 10.1186/1471-230X-11-91
  contributor:
    fullname: A Baranova
– volume: 95
  start-page: 314
  issue: 1124
  year: 2019
  ident: 489_CR9
  publication-title: Postgrad Med J
  doi: 10.1136/postgradmedj-2018-136316
  contributor:
    fullname: E Jennison
– volume: 18
  start-page: 5283
  issue: 37
  year: 2012
  ident: 489_CR25
  publication-title: World J Gastroenterol
  contributor:
    fullname: L Zhang
– volume: 53
  start-page: 726
  issue: 3
  year: 2011
  ident: 489_CR12
  publication-title: Hepatology
  doi: 10.1002/hep.24105
  contributor:
    fullname: ZH Lin
– ident: 489_CR13
– volume: 70
  start-page: 151
  issue: 1
  year: 2019
  ident: 489_CR1
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2018.09.014
  contributor:
    fullname: SK Asrani
– volume: 52
  start-page: 3404
  issue: 12
  year: 2007
  ident: 489_CR15
  publication-title: Dig Dis Sci
  doi: 10.1007/s10620-007-9758-8
  contributor:
    fullname: F Tacke
– volume: 12
  start-page: dmm038810
  issue: 7
  year: 2019
  ident: 489_CR21
  publication-title: Dis Model Mech
  doi: 10.1242/dmm.038810
  contributor:
    fullname: A Villar-Lorenzo
– volume: 9
  start-page: 875
  issue: 4
  year: 2020
  ident: 489_CR4
  publication-title: Cells
  doi: 10.3390/cells9040875
  contributor:
    fullname: N Roehlen
– volume: 94
  start-page: 2467
  issue: 9
  year: 1999
  ident: 489_CR23
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.1999.01377.x
  contributor:
    fullname: EM Brunt
– volume: 21
  start-page: 311
  issue: 3
  year: 2001
  ident: 489_CR5
  publication-title: Semin Liver Dis
  doi: 10.1055/s-2001-17550
  contributor:
    fullname: A Geerts
– volume: 56
  start-page: 102794
  year: 2020
  ident: 489_CR17
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2020.102794
  contributor:
    fullname: NE Owen
– volume: 3
  start-page: 1473
  issue: 4
  year: 2013
  ident: 489_CR24
  publication-title: Compr Physiol
  doi: 10.1002/cphy.c120035
  contributor:
    fullname: JE Puche
– volume: 59
  start-page: 1265
  issue: 9
  year: 2010
  ident: 489_CR11
  publication-title: Gut
  doi: 10.1136/gut.2010.216077
  contributor:
    fullname: S McPherson
SSID ssj0000884119
Score 2.2767084
Snippet Advanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this study, we assessed...
Background & Aims Advanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this...
Background & AimsAdvanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this...
BACKGROUND & AIMSAdvanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this...
Abstract Background & Aims Advanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease....
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 46
SubjectTerms Algorithms
Analysis
Animal experimentation
Animal models
Animals
Antibiotics
Bile ducts
Biomarkers
Biopsy
BMP8A
Bone morphogenetic proteins
Cell culture
Diet
Fibrosis
Glucose
Health aspects
Hepatic stellate cells
Hepatitis
Humidity
Liver
Liver cancer
Liver cirrhosis
Liver diseases
Liver fibrosis
Medical research
Medicine, Experimental
Morbidity
Mortality
mRNA
Non-invasive diagnosis
Patients
Risk factors
Secretion
Transforming growth factors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-ysOBFdNeP6ipRBA8Stm3SND0-F5dV0IOusLeQ5mMt7Kby2if43zuT9j1e8eBlry9TXjozyfyGzvyGkLfWBpXXNmehUpKJJncM0ubArBMeJ-PUJmCj8Jev8uKH-HxVXe2N-sKasIkeeFLcqWpdgDBvhAiVsEIZ0xikBG4KxOJ-4vnMy71kKt3BSomiaLZdMkqeDgK_uDEIUQy9tmHlIhIlwv5_r-W9uLSsmdwLQucPyYMZPdLVtOtH5J6PR-Rwmif555iYs25t0zyueE3bPnp624Mee3AS7FWkiZShi1StaDdQQ2P_299Q7MDHIp01HXsQwS83I93WBtAbLNygAbLqfuiGx-Ty_OPl2QWbZygwC5nfyLj0xjjvRCvb4FonwDaldQ1OG5O2sNxXlRXGQVYjbBEKuBxr1xqAZTxILvkTchBhu88IlTXngFYK44MRIKCUyYUHfOM4oAzeZuT9Vp3618SUoVOGoaSelK9B-TopX5cZ-YAa30kiy3X6AWyvZ9vr_9k-I2_QXhp5LCIWylybzTDoT9-_6RWkSRx7IeGf3s1CoQfLWTP3HcBbIfXVQvJkIQkHzS6Xt26h54M-6BLZdnAkOmzm9W4Zn8Titej7DcrkNcQUSMwy8nTyot17c0B4EkBxRtTCvxaKWa7E7meiAccpywBg-fO7UOULcr9MZ0Owsj4hB-N6418C3BrbV-lk_QUq_yd1
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA-6h-CL-G31lCiCDxKubbJp-iR7xx2n4CHnCfcW0nyshbM9t13B_96ZNl2vCL42U5pOZjK_SeaDkLfWBpUWNmVhqSQTZeoYuM2BWSc8dsYpTMBE4c9n8vSb-HS5vIwHbl0Mq5z2xGGjdq3FM_KDHMuaYO9p_uH6J8OuUXi7Glto3CZ7ecaVWpC9w-OzL-e7UxbQIZFl5ZQto-RBJ_DmjYGpYii9JctnFmko3P_v9nzDPs1jJ28Yo5P75F5EkXQ1LvsDcss3D8mdsa_k70fEHNUbO_Tlata0ahtPf7TAzxaEBXMW6VCcoW6oWtG6o4Y27S9_RTETH4N1NrRvgQRvcHo6xQjQKwzgoAG867aru8fk4uT44uiUxV4KzIIH2DMuvTHOO1HJKrjKCVij3LoSu45Jm1nul0srjAPvRtgsZLBJFq4yAM94kFzyJ2TRwHSfESoLzgG1ZMYHI4BAKZMKDzjHcUAbvErI-4md-nqsmKEHT0NJPTJfA_P1wHydJ-QQOb6jxGrXw4N2s9ZRebSqXACoZ4QIMDuhjCkNloUuM_THPE_IG1wvjfUsGgyYWZtt1-mPX8_1CtwljjmR8KV3kSi0sHLWxPwD-CssgTWj3J9RgsLZ-fAkFjoqfKf_imdCXu-G8U0MYmt8u0WatADbAg5aQp6OUrT7bw5ITwI4ToiaydeMMfORpv4-lAPHbssAZPnz_8_rBbmbD1IvWF7sk0W_2fqXAKj66lXUmj8h7B_b
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA_HieCL-G31lCiCDxJtmzRNH0TWw-MUzge9g3sLaT72Cmur7a54_70z2Xa54uHrZnY3ncxkfkNn5kfIK2uDSkubslAoyUSVOgZpc2DWCY_MOKUJ2Ch88lUen4kv58X5HpnojkYFDtemdsgnddav3v75dfkBHP59dHgl3w0CX6YxiD4MDbJicCXfyCEyYonXyQj3482slMgi10eeFikAyzKb-miu_ZlZrIoj_f-9uK9ErnlV5ZUwdXSH3B7xJV1sDeIu2fPtPXJzyzh5eZ-Yw6a3kbGrXdK6az390YGmOzAj7GakcWxD01K1oM1ADW27335FsUcfy3h6uu5ABN_trOlUPUBXWNpBA-Td3dAMD8jp0afTw2M2siwwC7nhmnHpjXHeiVrWwdVOwOnl1lXIRyZtZrkvCiuMg7xH2CxkcH2WrjYA3HiQXPKHZL-F7T4mVJacA57JjA9GgIBSJhUeEJDjgEN4nZA3kzr1z-0sDR1zECX1VvkalK-j8nWekI-o8Z0kzsGOH3T9Uo9upVXtAoBAI0SA3QllTGVwYHSVYabmeUJe4nlpnHTRYinN0myGQX_-_k0vIJHi2C0J__R6FAodnJw1Y2cCPBUOx5pJHswkwRXtfHkyCz1Zss5xHg-SpsNmXuyW8ZtY3tb6boMyaQlRB1K3hDzaWtHuuTlgQAmwOSFqZl8zxcxX2uYiDgpHHmaAuPzJ_7f9lNzKo9ULlpcHZH_db_wzgFrr-nn0n78o9SM1
  priority: 102
  providerName: Scholars Portal
Title Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis
URI https://www.ncbi.nlm.nih.gov/pubmed/37106416
https://www.proquest.com/docview/2815622953
https://search.proquest.com/docview/2807911585
https://pubmed.ncbi.nlm.nih.gov/PMC10142503
https://doaj.org/article/8bdf154a44f54c48aa9adb7e918626e3
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtx2AvY9_L1gVtDPYw1MSRIsuPaWjpAiml7aBvQtZHZkjsEieD_fe7U-wQs7e92GCdsay7093Pvg9Cvlob1DC1QxbGSjKRDR0D2ByYdcJjZ5zUBEwUnl_Lq59i9jB-OCKyzYWJQfs2L87K5eqsLH7F2MrHlR20cWKDm_kU-8uC6eaDY3IM9vcAo8f9VymRJFmbIaPkoBb4t42BeWIosRnDHjYcbKsU2Of8wCDFuv3_7s4H5qkbOnlgiy5fkOeNE0knu8m-JEe-fEWe7tpK_nlNzLRY29iWq1zQvCo9XVWwnBXICqYs0liboSipmtCipoaW1W-_pJiIj7E6a7qpgAR_4GxoGyJAlxi_QQOA66ou6jfk_vLifnrFmlYKzAIA3DAuvTHOO5HLPLjcCWDRyLoMm45Jm1jux2MrjANwI2wSEtgjU5cb8M54kFzyt-SkhOm-J1SmnIPTkhgfjAACpcxQeHBzHAdng-c98r1dTv24K5ihI9BQUu_4oIEPOvJBj3rkHFd8T4nFruOFar3QDcu1yl0AT88IEWB2QhmTGawKnSUIxzzvkS_IL43lLEqMl1mYbV3rH3e3egJoiWNKJDzpW0MUKuCcNU36AbwVVsDqUJ52KEHfbHe4FQvd6HutR1h0Bzujw2Q-74fxToxhK321RZphCqYF8FmPvNtJ0f69W2HsEdWRr87CdEdAOWI18FYZPvz_rR_Js1FUDsFG6Sk52ay3_hP4Wpu8T55MJrO7GZzPL65vbvvxmwUc50L1o9r9Be6uLJw
link.rule.ids 230,314,727,780,784,864,885,2102,2221,21388,24318,27924,27925,33744,33745,43805,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgK0QviGcJFDAIiQOymsReJzmhbdVqC-0KlUXqzXL8WCK1Sdlkkfj3zOSxNELiGk8UZzzj-caeByHvjfFpmJiQ-WkqmchCy8Bt9sxY4bAzTqI9JgqfL-T8u_h8Ob3sD9zqPqxy2BPbjdpWBs_ID2Isa4K9p_mnm58Mu0bh7WrfQuMu2cHK6dMJ2Tk8Xny92J6ygA6JKMqGbJlUHtQCb94YmCqG0puxeGSR2sL9_27Pt-zTOHbyljE6eUge9CiSzrplf0TuuPIxudf1lfz9hOijYm3avlzliuZV6eh1BfysQFgwZ5G2xRmKkqYzWtRU07L65a4oZuJjsM6aNhWQ4A1OQ4cYAXqFARzUg3dd1UX9lCxPjpdHc9b3UmAGPMCGcem0ts6KXObe5lbAGsXGZth1TJrIcDedGqEteDfCRD6CTTKxuQZ4xr3kkj8jkxKm-5xQmXAOqCXSzmsBBGmqQ-EA51gOaIPnAfk4sFPddBUzVOtppFJ1zFfAfNUyX8UBOUSObymx2nX7oFqvVK88Ks2tB6inhfAwO5FqnWksC51F6I85HpB3uF4K61mUGDCz0pu6VqffLtQM3CWOOZHwpQ89ka9g5Yzu8w_gr7AE1ohyf0QJCmfGw4NYqF7ha_VXPAPydjuMb2IQW-mqDdKECdgWcNACstdJ0fa_OSA9CeA4IOlIvkaMGY-UxY-2HDh2WwYgy1_8f15vyP358vxMnZ0uvrwku3GrAYLFyT6ZNOuNewXgqslf9xr0B7jTIsM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgEYgL4k1hAYOQOKBsmtp1nGMpVLvArlawSHuzHD9KpNapmhaJf8-Mm1SNuHGtJ6rjmfHMKN98Q8g7Y7wc5maY-LEUCS-GNoGy2SfGcoeTcXLtsVH4_EKc_uRfrsfXLaqyaWGVwZTVSVgsT0L1K2IrV0uTdjix9PJ8ivNlIXSzdGV9epPcGjOwsoNKPd7CUvIsK7o-GSnShuM3twSCVIJ2WyQ4yYZBhBUcp50fhKXI3v_vHX0QpPoAyoOINLtP7rWpJJ3stvyA3HDhIbm9Gy755xHR02pt4nCuMKdlHRxd1nCoNVgMNi7SyNBQBSontGqopqH-7RYU2_ERsbOmmxpE8DPOhnZAAbpAFAf1UGLXTdU8Jlezz1fT06QdqJAYKAM3CRNOa-ssL0XpbWk5KGpkbIGjx4TJDHPjseHaQonDTeYzuClzW2rI0ZgXTLAn5CjAdp8RKnLGIHXJtPOag4CUesgdJDuWQcrBygH50B2nWu1oM1QsN6RQOz0o0IOKelCjAfmIJ76XRMrr-EO9nqtW8UqW1kO-pzn3sDsutS40ckMXGRZljg3IW9SXQlKLgKiZud42jTr78V1NoGZi2BgJ__S-FfI1aM7otgkB3gp5sHqSxz1J8DrTX-7MQrVe36gRUu_gfHTYzJv9Mj6JSLbg6i3KDHMIMFClDcjTnRXt37szxgGRPfvqHUx_BVwkcoJ3LvH8_x99Te5cfpqpb2cXX1-Qu6PoJzwZ5cfkaLPeupeQfG3KV9HL_gI_lywP
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circulating+bone+morphogenetic+protein+8A+is+a+novel+biomarker+to+predict+advanced+liver+fibrosis&rft.jtitle=Biomarker+research&rft.au=Mara%C3%A9%C3%B3n%2C+Patricia&rft.au=Isaza%2C+Stephania+C&rft.au=Fern%C3%A1ndez-Garc%C3%ADa%2C+Carlos+Ernesto&rft.au=Rey%2C+Esther&rft.date=2023-04-27&rft.pub=BioMed+Central+Ltd&rft.issn=2050-7771&rft.eissn=2050-7771&rft.volume=11&rft.issue=1&rft_id=info:doi/10.1186%2Fs40364-023-00489-2&rft.externalDocID=A747319562
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2050-7771&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2050-7771&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2050-7771&client=summon